Aprea Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Reuters08-12

* Aprea Therapeutics Inc reported a quarterly adjusted loss of 58 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -87 cents. The mean expectation of three analysts for the quarter was for a loss of 63 cents per share. Wall Street expected results to range from -69 cents to -58 cents per share.

* Revenue rose 124.8% to $562.00 thousand from a year ago; analysts expected $50.00 thousand.

* Aprea Therapeutics Inc's reported EPS for the quarter was a loss of 58 cents​.

* The company reported a quarterly loss of $3.47 million.

* Aprea Therapeutics Inc shares had fallen by 17.4% this quarter and lost 28.5% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 21.2% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Aprea Therapeutics Inc is $16.00 This summary was machine generated from LSEG data August 12 at 02:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Jun. 30 2024 -0.63 -0.58 Beat

Mar. 31 2024 -0.78 -0.67 Beat

Dec. 31 2023 -0.77 -0.92 Missed

Sep. 30 2023 -1.16 -0.86 Beat

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment